BSE Live
Dec 23, 13:02Prev. Close
1283.85
Open Price
1286.50
Bid Price (Qty.)
1280.55 (1)
Offer Price (Qty.)
1281.00 (83)
NSE Live
Dec 23, 13:02Prev. Close
1283.40
Open Price
1288.60
Bid Price (Qty.)
1280.50 (88)
Offer Price (Qty.)
1280.70 (182)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,899.60 | 2,646.30 | 2,164.70 | 1,804.40 | 1,182.80 | |
| Net CashFlow From Operating Activities | 2,523.50 | 1,969.70 | 1,377.90 | 1,612.60 | 755.40 | |
| Net Cash Used In Investing Activities | -2,264.70 | -1,694.10 | -1,446.30 | -1,020.60 | -898.80 | |
| Net Cash Used From Financing Activities | -433.20 | -24.20 | -156.80 | 389.10 | 44.50 | |
| Foreign Exchange Gains / Losses | -105.10 | 90.60 | 9.40 | 49.90 | 14.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -279.50 | 342.00 | -215.80 | 1,031.00 | -84.90 | |
| Cash And Cash Equivalents Begin of Year | 862.40 | 520.40 | 736.20 | 575.10 | 660.00 | |
| Cash And Cash Equivalents End Of Year | 582.90 | 862.40 | 520.40 | 1,606.10 | 575.10 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz